VNA
MRNA icon

Valley National Advisers’s Moderna MRNA Stock Holding History

Valley National Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Hold
329
– – ﹤0.01% 499
2026
Q1 		$16K Sell
329
-287
-47% -$13.4K ﹤0.01% 535
2025
Q4 		$18K Sell
616
-15
-2% -$408 ﹤0.01% 519
2025
Q3 		$16K Sell
631
-142
-18% -$3.96K ﹤0.01% 498
2025
Q2 		$21K Buy
773
+14
+2% +$369 ﹤0.01% 477
2025
Q1 		$21K Buy
759
+365
+93% +$13K ﹤0.01% 479
2024
Q4 		$16K Hold
394
– – ﹤0.01% 478
2024
Q3 		$26K Sell
394
-90
-19% -$8.26K ﹤0.01% 423
2024
Q2 		$57K Buy
484
+20
+4% +$2.53K 0.01% 373
2024
Q1 		$49K Sell
464
-48
-9% -$4.84K 0.01% 404
2023
Q4 		$50K Sell
512
-26
-5% -$2.19K 0.01% 402
2023
Q3 		$56K Buy
538
+2
+0.4% +$223 0.01% 372
2023
Q2 		$66K Buy
536
+9
+2% +$1.2K 0.01% 357
2023
Q1 		$73K Buy
527
+100
+23% +$16.5K 0.01% 336
2022
Q4 		$79K Buy
427
+48
+13% +$7.85K 0.01% 331
2022
Q3 		$51K Buy
379
+4
+1% +$607 0.01% 374
2022
Q2 		$65K Buy
375
+46
+14% +$6.58K 0.01% 321
2022
Q1 		$57K Buy
329
+88
+37% +$14.8K 0.01% 351
2021
Q4 		$61K Buy
241
+37
+18% +$10.8K 0.01% 334
2021
Q3 		$79K Buy
204
+6
+3% +$2.21K 0.01% 302
2021
Q2 		$47K Buy
198
+12
+6% +$2.15K 0.01% 353
2021
Q1 		$24K Buy
186
+13
+8% +$1.88K ﹤0.01% 424
2020
Q4 		$18K Sell
173
-50
-22% -$5.06K ﹤0.01% 451
2020
Q3 		$16K Hold
223
– – ﹤0.01% 428
2020
Q2 		$14K Sell
223
-174
-44% -$9.53K ﹤0.01% 443
2020
Q1 		$12K Buy
+397
New +$9.13K ﹤0.01% 449

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Valley National Advisers's MRNA Position: Q2 2026 in Review

Valley National Advisers held its Moderna (MRNA) position steady in Q2 2026 at 329 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #499.

Valley National Advisers first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $79K in Q4 2022. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Valley National Advisers held 329 shares of Moderna worth $23K as of Q2 2026.
  • Valley National Advisers left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #499 holding.
  • Valley National Advisers first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Valley National Advisers's Moderna position peaked at $79K in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.